Drug intelligence / Profile preview

HTPEP-712

Development stage: Preclinical
Lead developer: Chengdu Huitai Biomedical
Modality: Peptides

Overview

HTPEP-712 is a preclinical-stage anti-aging peptide being developed by Chengdu Huitai Biopharmaceutical for cosmetic medicine applications, specifically targeting skin aging. While the company's core expertise lies in developing TGF-β1 inhibitors for fibrotic diseases (such as idiopathic pulmonary fibrosis and liver cirrhosis), HTPEP-712 represents a diversification into the aesthetic and cosmetic dermatology market. The specific molecular target and detailed mechanism of action for HTPEP-712 have not been publicly disclosed, but it leverages the company's research into tissue remodeling and fibrosis pathways.

Beyond the preview

Go deeper on HTPEP-712.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTPEP-712.

Explore the full profile